Literature DB >> 35933608

COVID-19 and Acute Pancreatitis: A Systematic Review of Case Reports and Case Series.

Vasiliki E Georgakopoulou1, Aikaterini Gkoufa2, Nikolaos Garmpis3, Sotiria Makrodimitri1, Chrysovalantis V Papageorgiou1, Danai Barlampa4, Anna Garmpi2, Serafeim Chiapoutakis5, Pagona Sklapani6, Nikolaos Trakas7, Christos Damaskos8.   

Abstract

BACKGROUND: Coronavirus disease 2019 (COVID-19) presents mainly with mild symptoms and involvement of the respiratory system. Acute pancreatitis has also been reported during the course of COVID-19.
OBJECTIVE: Our aim is to review and analyze all reported cases of COVID-19 associated acute pancreatitis, reporting the demographics, clinical characteristics, laboratory and imaging findings, comorbidities and outcomes. DATA SOURCES: We conducted a systematic search of Pubmed/MEDLINE, SciELO and Google Scholar to identify case reports and case series, reporting COVID-19 associated acute pancreatitis in adults. STUDY SELECTION: There were no ethnicity, gender or language restrictions. The following terms were searched in combination:"COVID-19" OR "SARS-CoV-2" OR "Coronavirus 19" AND "Pancreatic Inflammation" OR "Pancreatitis" OR "Pancreatic Injury" OR "Pancreatic Disease" OR "Pancreatic Damage". Case reports and case series describing COVID-19 associated acute pancreatitis in adults were included. COVID-19 infection was established with testing of nasal and throat swabs using reverse transcription polymerase chain reaction. The diagnosis of acute pancreatitis was confirmed in accordance to the revised criteria of Atlanta classification of the Acute Pancreatitis Classification Working Group. Exclusion of other causes of acute pancreatitis was also required for the selection of the cases. DATA EXTRACTION: The following data were extracted from each report: the first author, year of publication, age of the patient, gender, gastrointestinal symptoms due to acute pancreatitis, respiratory-general symptoms, COVID-19 severity, underlying diseases, laboratory findings, imaging features and outcome. DATA SYNTHESIS: Finally, we identified and analyzed 31 articles (30 case reports and 1 case series of 2 cases), which included 32 cases of COVID-19 induced acute pancreatitis.
CONCLUSION: COVID-19 associated acute pancreatitis affected mostly females. The median age of the patients was 53.5 years. Concerning laboratory findings, lipase and amylase were greater than three times the ULN while WBC counts and CRP were elevated in the most of the cases. The most frequent gastrointestinal, respiratory and general symptom was abdominal pain, dyspnea and fever, respectively. The most common imaging feature was acute interstitial edematous pancreatitis and the most frequent comorbidity was arterial hypertension while several patients had no medical history. The outcome was favorable despite the fact that most of the patients experienced severe and critical illness. LIMITATIONS: Our results are limited by the quality and extent of the data in the reports. More specifically, case series and case reports are unchecked, and while they can recommend hypotheses they are not able to confirm robust associations. CONFLICT OF INTEREST: None.

Entities:  

Mesh:

Year:  2022        PMID: 35933608      PMCID: PMC9357298          DOI: 10.5144/0256-4947.2022.276

Source DB:  PubMed          Journal:  Ann Saudi Med        ISSN: 0256-4947            Impact factor:   1.707


INTRODUCTION

Acute pancreatitis is the leading cause of hospital admission for disorders of the gastrointestinal tract in several countries.[1] Gallstones and alcohol overconsumption are well-established risk factors. Other factors, possibly genetic, probably have a role. Drugs are an additional causative factor of acute pancreatitis. Moreover, smoking and diabetes type II increase the probability of acute pancreatitis development. Mild cases are generally successfully managed with a conservative approach. Severe cases frequently need admission to an intensive care unit for monitoring and managing complications of the disease, which are related to high rates of mortality, even when the treatment is optimal.[2] Approximately 10% of cases of acute pancreatitis are considered to have infectious microorganisms as an underlying cause.[3] These microorganisms include viruses (like Coxsackie B and hepatitis), bacteria (like Mycoplasma pneumonia and Leptospira), and parasites (like Ascaris lumbricoides and Fasciola hepatica). Each microorganism leads to acute pancreatitis through various mechanisms.[3] Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly worldwide and is characterized by the World Health Organization as an international public health emergency. Besides typical symptoms and signs from respiratory system, acute pancreatitis has been reported during the course of the disease.[4] COVID-19 associated pancreatic inflammation results from the expression of angiotensin converting enzyme 2 (ACE2) receptors in pancreatic tissue. The structural protein glycosylated-spike (S) protein, encoded by SARS-CoV-2 genome, primarily induces the immune response of the host. The S protein binds to ACE2 receptor sites on the cell surface membrane mediating the cell invasion. ACE2 receptors are not only expressed in lung alveolar type-2 cells. ACE2 receptors are expressed in the pancreas, in both exocrine glands and islets, in a higher grade than in the lungs.[5,6] This expression of ACE2 receptors can lead to pancreatic cell damage during COVID-19 infection. Direct cytotoxic action of SARS-CoV-2 or indirect, immune-mediated, systemic inflammation could be the mechanism of pathogenesis for pancreatic injury.[5,6] Globally, the incidence of acute pancreatitis ranges between 5 and 80 per 100 000 population, with the highest incidence observed in the United States and Finland.[7] The incidence of SARS-CoV-2 infection varies among regions. Cyprus has the highest incidence of COVID-19 cases among its population in Europe at 55 424 per 100 000 people, followed by a rate of 52 738 per 100 000 in Iceland.[8] In United States the incidence ranges between 2698 cases per 100 000 population in Hawaii and 14 541 cases per 100 000 population in North Dakota.[8] In this study, we aimed to review and analyze all reported cases of COVID-19 associated acute pancreatitis, reporting the demographics, clinical characteristics, laboratory and imaging findings, comorbidities and outcomes.

CASES AND METHODS

Search strategy and article selection

We conducted a systematic search of Pubmed/MEDLINE, SciELO and Google Scholar to identify case reports and case series, reporting COVID-19 associated acute pancreatitis in adults, using the Patient, Intervention, Comparison and Outcome (PICO) Model.[9] There were no ethnicity or gender restrictions. In addition, there were no language restrictions. We assessed all articles published from 01 January 2020 to 20 April 2021. A protocol of the study, including details of the methods used in the systematic review has been deposited in the PROSPERO database () with the registration number CRD42021266917. The following terms were searched in combination:“COVID-19” OR “SARS-CoV-2” OR “Coronavirus 19” AND “Pancreatic Inflammation” OR “Pancreatitis” OR “Pancreatic Injury” OR “Pancreatic Disease” OR “Pancreatic Damage”. The search was conducted by two reviewers (VEG, CD). Articles were first screened for relevance by title. Then they were evaluated by abstract. The relevant case reports were enrolled for full-text review. Moreover, a manual search of the lists of the references of these texts was performed for identifying additional relevant case reports and case series. Case reports and case series describing COVID-19 associated acute pancreatitis in adults were included. COVID-19 infection was established with testing of nasal and throat swabs using reverse transcription polymerase chain reaction. The diagnosis of acute pancreatitis was confirmed in accordance to the revised criteria of the Atlanta Acute Pancreatitis Classification Working Group.[10] At least two of the following three criteria had to be present for a diagnosis of acute pancreatitis: a) typical pain of acute pancreatitis (acute onset of a severe and persistent epigastric pain often with radiation to the back) b) serum lipase or amylase elevated at least three times the upper limit of normal; c) compatible imaging findings of acute pancreatitis on abdominal computed tomography (CT), on magnetic resonance imaging (MRI) or abdominal ultrasonography (U/S).[10] Exclusion of other causes of acute pancreatitis was also required for the selection of the cases.

Data extraction

The following data were extracted from each report: the first author, year of publication, age of the patient, gender, gastrointestinal symptoms due to acute pancreatitis, respiratory-general symptoms, COVID-19 severity, underlying diseases, laboratory findings, imaging features and outcome. The tool suggested by Murad et al to assess the methodological quality and synthesis of the case series and case reports was utilized.[11] The possible best score was 6 for a case report or a case series of good quality. The patients represented the whole experience of the researchers, the diagnosis of SARS-CoV-2 and the outcomes were adequately ascertained; other causes of pancreatitis were excluded. The follow-up was long enough for outcomes to occur and the described cases had sufficient details to allow other researchers to replicate the findings. shows the use of the tool suggested by Murad et al in our review. In addition, we followed the PRISMA (Preferred Reporting Items For Systematic Reviews And Meta-Analyses) guidelines for writing this review.[12] Tool for evaluating the methodological quality of case reports and case series of the current review suggested by Murad et al.[11] The statistical analysis of data was performed with IBM SPSS for Windows, Version 13.0 (Armonk, New York, United States: IBM Corp). Continuous variables were tested for normality of distribution by the Kolmogorov-Smirnov test. For normally distributed values, descriptive results are presented as mean (standard deviation) and median while categorical variables are mentioned as numbers and percentages. The meta-regression analysis was performed using a random-effects model and stepwise selection of variables.[13] To determine if the findings affected the severity of COVID-19, we used a meta-regression analysis using the following equations: Severity1=ß0+ß1*log1(lipase) and Severity2=ß0+ß1*log2(amylase).

RESULTS

The systematic search identified 71 possibly relevant records after review of the title, abstract or full text screening, and after exclusion of duplicates (). Forty records were excluded after careful screening of the titles and abstracts, since they did not mention COVID-19 associated with acute pancreatitis presented as case reports or case series. Finally, we identified 31 articles (30 case reports and 1 case series of 2 cases), which included 32 cases of COVID-19 induced acute pancreatitis ().[14-44] Nineteen patients were females (59.4%) and 13 patients were males (40.6%). The median age was 53.5 years (range 20-76 years). The median age of the females was 52 years (range 20-76 years) (median 52) years and the median age of the males was 48 (24-68) years. Flow diagram for study selection. Demographic and clinical characteristics including COVID-19 severity and outcome of patients with COVID-19-induced acute pancreatitis. HELLP: Hemolysis, Elevated Liver Enzymes, Low Platelet Count. Laboratory and Imaging findings among the 32 cases following development of acute pancreatitis. CRP: C-reactive protein; CT: Computerized tomography; MRI: Magnetic resonance imaging, U/S: Ultrasonography, ULN: Upper limit of normal, WBC: White blood cells. Demographic and clinical data from the 32 cases. Data are n (%); ULN: Upper limit of normal. The majority of the patients had abdominal pain as clinical manifestation (28/32, 87.5%). Other gastrointestinal symptoms were nausea, vomiting, diarrhea, constipation, anorexia and lack of flatus, while 2 (6.3%) of the patients presented with no gastrointestinal symptoms. Twenty (62.5%) patients presented with dyspnea and 14 (43.8%) presented with cough. A majority of patients had fever (59.4%). Four (12.5%) patients had no respiratory or general symptoms, while 2 (6.3%) patients had no respiratory symptoms. According to classification into severity of illness categories by National Institutes of Health (NIH),[45] 8 (25%) patients had mild SARS-CoV-2 illness, 4 (12.5%) patients had moderate SARS-CoV-2 illness, 10 (31.2%) patients had severe SARS-CoV-2 illness and 10 (31.2%) patients had critical SARS-CoV-2 illness (). The data on serum amylase levels in 27 patients was over three times the upper limit of normal (ULN), while the rest had amylase levels less than three times of ULN. Data about lipase levels were available in 22 patients. The majority of these patients (21/22, 95.5%) had lipase levels over three times of ULN while only 1 patient (1/22, 0.5%) had lipase levels less than three times of ULN. Data about white blood cells (WBC) count were available in 26 patients. Twelve patients (12/26, 46.2%) had elevated WBC count, 12 (46.2%) had WBC count with normal limits while 2 (7.6%) had decreased WBC count. Data on C-reactive protein were available in 20 patients. Eighteen patients (90%) had elevated levels of CRP while 2 (10%) had CRP levels within normal limits. Imaging data were available in 31 patients (). Twenty-one (67.8%) of the patients had abdominal CT or MRI features compatible with acute interstitial edematous pancreatitis. Medical history data were available in 31 patients. Arterial hypertension was most common, followed by diabetes mellitus, obesity, cholecystectomy and others. Two female patients were pregnant while 12 patients (38.5%) had no medical history. Data on outcome were available in 30 cases. All these patients recovered (30/30, 100%). In two cases, the outcome was unknown because the article was published while patients were still hospitalized. The meta-regression analysis included the 30 articles that presented full laboratory findings following development of acute pancreatitis (). The R value of 0.461 represents the simple correlation, which indicates a moderate degree of correlation. The R2 value indicates how much of the total variation in severity, the dependent variable, was explained by the independent variables. In this case, R2 indicated that only 21.3% could be explained by the independent variables. The association of the regression model was statistically significant (i.e., a good fit for the data) (P<.05) (). Data for the meta-regression meta-analysis. ULN: Upper limit of normal Results of the regression analysis for lipase (n=24). Severity1=−,484+753*log1(lipase) Results of the regression analysis for amylase lipase (n=27). Severity2=−,484+1,1223*log2(amylase)

DISCUSSION

There are very few case reports and case series describing COVID-19 induced acute pancreatitis. To our knowledge, we present the largest and most comprehensive systematic review of case reports and case series on SARS-CoV-2 infection causing acute pancreatitis. The ages of the patients were uniformly distributed with a median age of 53.5 years. The majority of the patients were females. Lipase and amylase were greater than three times the ULN while WBC counts and CRP were elevated in the most of the cases. The majority of the patients mentioned abdominal pain while other frequent symptoms were nausea and vomiting. The most common respiratory symptoms were dyspnea and cough. Fever was the most frequent general symptom and in some cases neither respiratory nor general symptoms were present. Most of the patients experienced severe and critical SARS-CoV-2 illness. The imaging features of abdominal CT were mostly compatible with acute interstitial edematous pancreatitis. The most frequent comorbidity was arterial hypertension and 38.5% of the patients had no medical history. In addition, where data were available, all the patients recovered. The results of meta-regression analysis showed a low heterogeneity between the studies regarding the severity of COVID-19 disease and that serum levels of lipase and amylase had a moderate positive correlation with the severity of COVID-19 disease. Data from studies about COVID-19 patients presenting with acute pancreatitis are limited. Szatmary et al in a study of hospitalized patients for acute pancreatitis found only 5 patients with SARS-CoV-2 infection in whom other causes of acute pancreatitis were excluded. All the patients were young adult males with a median age of 42 years and all were obese with no history of cardiovascular disease. There were no data about serum lipase levels; serum amylase levels were increased. Abdominal CT was used to establish the final diagnosis. The finding of pancreatic inflammation on CT was mild pancreatic edema without pancreatic or peripancreatic necrosis, compatible with acute interstitial edematous pancreatitis. In this study, all patients with COVID-19 associated acute pancreatitis recovered.[46] Our systematic review was written after a comprehensive search of the literature with specific criteria for inclusion and quality assessment. However, our results are limited by the quality and extent of the data in the reports. More specifically, case series and case reports are unchecked, and while they can recommend hypotheses they are not able to confirm robust associations. Clinicians should be aware of the few cases reported in the literature, suggesting that acute pancreatitis can result from COVID-19. While case reports can provide signals, they are not strong enough for statistical inference. Thus, the evidence provided is insufficient to suggest systematic screening in patients with COVID-19 for pancreatic involvement, but should alert physicians of possible pancreatic involvement by SARS-CoV-2. In conclusion, COVID-19 associated acute pancreatitis affected mostly females with a median age of 53.5 years. Concerning laboratory findings, lipase and amylase were greater than three times the ULN while WBC counts and CRP were elevated in the most of the cases. The most frequent gastrointestinal, respiratory and general symptom was abdominal pain, dyspnea and fever, respectively. The most common imaging feature was acute interstitial edematous pancreatitis and the most frequent comorbidity was arterial hypertension while several patients had no medical history. The outcome was favorable despite the fact that most of the patients experienced severe and critical illness. Our results warrant the need for larger controlled research to detect acute pancreatitis during COVID-19 course and to provide data on patient characteristics and outcomes.
Table 1.

Tool for evaluating the methodological quality of case reports and case series of the current review suggested by Murad et al.[11]

DomainsLeading explanatory questionsCases and cases series included in the current reviewScore
Selection1. Does the patient(s) represent(s) the whole experience of the investigator (center) or is the selection method unclear to the extent that other patients with similar presentation may not have been reported?Yes1
Ascertainment2. Was the exposure adequately ascertained?Yes1
3. Was the outcome adequately ascertained?Yes1
4. Were other alternative causes that may explain the observation ruled out?Yes1
Causality5. Was there a challenge/rechallenge phenomenon?No0
6. Was there a dose-response effect?No0
7. Was follow-up long enough for outcomes to occur?Yes1
Reporting8. Is the case(s) described with sufficient details to allow other investigators to replicate the research or to allow practitioners make inferences related to their own practice?Yes1
Total Score 6
Table 2.

Demographic and clinical characteristics including COVID-19 severity and outcome of patients with COVID-19-induced acute pancreatitis.

#Author, YearAge/GenderMedical historyGastrointestinal manifestationsRespiratory-general symptomsSeverity of COVID-19Outcome
1Meyers, 2020[14]67/MArterial hypertensionCholecystectomyAlcohol useAbdominal painDyspneaFeverSevereRecovered
2Karimzadeh, 2020[15]65/FArterial hypertensionAsthmaAbdominal painNauseaDyspneaChillsMyalgiaSevereRecovered
3Shinohara, 2020[16]58/MArterial hypertensionAbdominal painDyspneaFeverCriticalRecovered
4Rabice, 2020[17]36/FPregnancyDiabetes mellitusAsthma ObesityAbdominal painNauseaVomitingDry coughFeverMyalgiaSevereRecovered
5Meireles, 2020[18]36/FPost-HELLP syndromeStage V chronic kidney diseaseArterial hypertensionAbdominal painNauseaVomitingDry coughDyspneaFeverModerateRecovered
6Fernandes, 2020[19]36/FNo medical historyAbdominal painDyspneaFeverHeadacheModerateRecovered
7Alwaeli, 2020[20]30/MNo medical historyAbdominal painNauseaVomitingDiarrheaDry coughDyspneaFeverCriticalRecovered
8Narang, 2020[21]20/FPregnancyObesityCholocystectomyAbdominal painNauseaVomitingDyspneaCriticalRecovered
9Kandasamy, 2020[22]45/FNo medical historyAbdominal painNauseaVomitingDyspneaSevereRecovered
10Kumaran, 2020[23]67/FLaparotomy and small bowel resection and anastomosis of superior mesenteric artery stenosisArterial hypertensionAbdominal painDiarrheaVomitingDyspneaSevereRecovered
11Acherjya, 2020[24]57/FArterial hypertension Diabetes mellitusActive malignancy of breast and larynxAbdominal painVomitingNo respiratory symptomsFeverGeneralized body acheLoss of smellFatigueArthralgiaSevereRecovered
12Bokhari, 2020[25]32/MNo medical historyAbdominal painVomitingProductive coughFeverMyalgiaMildRecovered
13Mazrouei, 2020[26]24/MN/AAbdominal painNauseaVomitingNo respiratory-other symptomsMildRecovered
14Patnaik, 2020[27]29/MNo medical historyAbdominal painDyspneaFeverModerateRecovered
15Schepis, 2020[28]67/FRecent hospitalization for InterstitialEdematous acute pancreatitis of unknown originAbdominal painVomitingNo respiratory-other symptomsMildRecovered
16Aloysius, 2020[29]36/FChronic anxietyObesityAbdominal painNauseaVomitingDiarrheaDry coughDyspneaFeverCriticalRecovered
17Gonzalo-Voltas, 2020[30]76/FHypercholesterolemiaGastroesophageal refluxAbdominal painVomitingNo respiratory-other symptomsMildRecovered
18Alves, 2020[31]56/FArterial hypertensionAbdominal painDry coughDyspneaFatigueCriticalRecovered
19Ghosh, 2020[32]63/MDiabetes mellitusNo Gastrointestinal SymptomsDyspneaDry coughFeverSevereRecovered
20Kataria, 2020[33]49/FNo medical historyAbdominal painNauseaVomitingDyspneaDry coughLethargyFeverCriticalRecovered
21Hadi, 2020[34]47/FNo medical historyAnorexiaDyspneaFeverHeadacheNeck PainSore ThroatCriticalN/A
22Hadi, 2020[34]68/FArterial hypertensionHypothyroidismOsteoporosisAbdominal painVomitingDiarrheaFeverFatiguePolydipsiaCriticalN/A
23Brikman, 2020[35]61/MNo medical historyAbdominal painDyspneaCoughFeverCriticalRecovered
24Lakshmanan, 2020[36]68/MNursing home residentDiabetes mellitusArterial hypertensionStage IV chronic kidney diseaseAnorexiaNauseaVomitingNo respiratory-other symptomsMildRecovered
25Miao, 2020[37]26/FNo medical historyAbdominal painVomitingNo respiratory symptoms FeverMildRecovered
26Pinte, 2020[38]47/MNo medical historyAbdominal painNauseaConstipationLack of flatusDry coughMildRecovered
27Anand, 2020[39]59/FCholecystectomyThrombophiliaAbdominal painConstipationCoughFeverSore ThroatMyalgiaMildRecovered
28Wifi, 2021[40]72/FObesityArterial hypertensionIschemic heart diseaseAbdominal painNauseaVomitingCoughNasal SneezingSevereRecovered
29Mohammadi Arbati, 2021[41]28/MNo medical historyAbdominal painNauseaVomitingDyspneaDry coughFeverMyalgiaCriticalRecovered
30Maalouf, 2021[42]62/MArterial hypertensionDiabetes mellitusEnd-stage renal disease statusPost Kidney TransplantAbdominal painDiarrheaVomitingAnorexiaDyspneaModerateRecovered
31AlHarm, 2021[43]52/FDiabetes mellitusArterial hypertensionHypothyroidismObesityAbdominal painNauseaVomitingDry coughDyspneaFeverSevereRecovered
32Chivato Martín-Falquina, 2021[44]55/MNo medical historyNo Gastrointestinal SymptomsDyspneaSevereRecovered

HELLP: Hemolysis, Elevated Liver Enzymes, Low Platelet Count.

Table 3.

Laboratory and Imaging findings among the 32 cases following development of acute pancreatitis.

#Author, YearLipase (U/L)Amylase (U/L)WBC/CRPAbdominal imaging features
1Meyers, 2020[14]>3 times of UNLN/AN/A/N/AAbdominal CT: acute interstitial edematous pancreatitis.
2Karimzadeh, 2020[15]>3 times of UNL<3 times of ULNNormal/N/AAbdominal CT: no abnormal findings.
3Shinohara, 2020[16]N/A>3 times of UNLNormal/ElevatedAbdominal CT: acute interstitial edematous pancreatitis.
4Rabice, 2020[17]>3 times of UNL<3 times of ULNNormal/N/AAbdominal CT was not recommended as it would not change clinical management.
5Meireles, 2020[18]>3 times of UNL>3 times of UNLN/A/ElevatedAngio-abdominal CT: exclusion of ischemic changes
6Fernandes, 2020[19]>3 times of UNL>3 times of UNLN/A/N/AAbdominal CT: acute interstitial edematous pancreatitis.
7Alwaeli, 2020[20]>3 times of UNL<3 times of ULNNormal/N/AAbdominal CT: acute interstitial edematous pancreatitis.
8Narang, 2020[21]>3 times of UNL>3 times of UNLElevated/N/AAbdominal MRI: acute interstitial edematous pancreatitis.
9Kandasamy, 2020[22]>3 times of UNL>3 times of UNLElevated/N/AAbdominal CT: acute interstitial edematous pancreatitis.
10Kumaran, 2020[23]N/A>3 times of UNLElevated/ElevatedAbdominal CT: necrotizing pancreatitis
11Acherjya, 2020[24]>3 times of UNL<3 times of UNLDecreased/ElevatedAbdominal CT: acute interstitial edematous pancreatitis.
12Bokhari, 2020[25]>3 times of UNL>3 times of UNLElevated/ElevatedAbdominal CT: acute interstitial edematous pancreatitis.
13Mazrouei, 2020[26]>3 times of UNL>3 times of UNLN/A N/AAbdominal CT: acute interstitial edematous pancreatitis.
14Patnaik, 2020[27]>3 times of UNL>3 times of UNLElevated/ElevatedAbdominal CT, Abdominal U/S : acute interstitial edematous pancreatitis and no evidence of common bile duct calculi.
15Schepis, 2020[28]N/A>3 times of UNLNormal/N/AAbdominal CT: large pancreatic pseudocyst causing a partial stomach outlet obstruction
16Aloysius, 2020[29]>3 times of UNL>3 times of UNLNormal/ElevatedAbdominal CT: normal gall bladder, biliary tract, with unremarkable pancreas.
17Gonzalo-Voltas, 2020[30]N/A>3 times of UNLElevated/ElevatedAbdominal CT: acute interstitial edematous pancreatitis.
18Alves, 2020[31]>3 times of UNL>3 times of UNLN/A/N/AAbdominal CT: acute interstitial edematous pancreatitis.
19Ghosh, 2020[32]<3 times of UNL<3 times of UNLNormal/ElevatedAbdominal CT: necrotizing pancreatitis
20Kataria, 2020[33]>3 times of UNL>3 times of UNLNormal/ElevatedAbdominal CT: acute interstitial edematous pancreatitis.
21Hadi, 2020[34]N/A>3 times of UNLNormal/ElevatedAbdominal U/S: acute interstitial edematous pancreatitis.
22Hadi, 2020[34]N/A>3 times of UNLNormal/ElevatedN/A
23Brikman, 2020[35]>3 times of UNL<3 times of UNLElevated/N/AAbdominal CT: acute interstitial edematous pancreatitis.
24Lakshmanan, 2020[36]>3 times of UNL>3 times of UNLNormal/ElevatedAbdominal CT: acute interstitial edematous pancreatitis (peripancreatic fat stranding, greatest around the tail, with mild duodenal wall thickening and adjacent fat stranding)
25Miao, 2020[37]>3 times of UNLN/ANormal/ElevatedAbdominal CT, abdominal U/S: acute interstitial edematous pancreatitis.
26Pinte, 2020[38]N/AN/AElevated/ElevatedAbdominal CT: acute interstitial edematous pancreatitis.
27Anand, 2020[39]N/AN/AElevated/ElevatedAbdominal CT: acute interstitial edematous pancreatitis.
28Wifi, 2021[40]>3 times of UNL>3 times of UNLElevated/ElevatedAbdominal CT: without abnormal findings
29Mohammadi Arbati, 2021[41]>3 times of UNL>3 times of UNLElevated/NormalAbdominal CT: necrotizing pancreatitis
30Maalouf, 2021[42]>3 times of UNLN/ADecreased/ElevatedAbdominal MRI: necrotizing pancreatitis
31AlHarm, 2021[43]N/A<3 times of UNLElevated/NormalAbdominal CT: acute interstitial edematous pancreatitis.
32Chivato Martín-Falquina, 2021[44]N/A>3 times of UNLN/A N/AAbdominal CT: acute interstitial edematous pancreatitis.

CRP: C-reactive protein; CT: Computerized tomography; MRI: Magnetic resonance imaging, U/S: Ultrasonography, ULN: Upper limit of normal, WBC: White blood cells.

Table 4.

Demographic and clinical data from the 32 cases.

Demographics
Gender
 Males13/32 (59.4)
 Females19/32 (40.6)
Gastrointestinal symptoms
 Abdominal pain28/32 (87.5)
 Nausea14/32 (43.8)
 Vomiting20/32 (62.5)
 Diarrhea5/32 (15.6)
 Constipation2/32 (6.3)
 Anorexia3/32 (9.3)
 Lack of flatus1/32 (3.1)
 No gastrointestinal symptoms2/32 (6.3)
Respiratory/General symptoms
 Dyspnea20/32 (62.5)
 Cough14/32 (43.8)
 Fever19/32 (59.4)
 Myalgia4/32 (12.5)
 Fatigue3/32 (9.3)
 Headache2/32 (6.3)
 No respiratory or general symptoms4/32 (12.5)
 No respiratory symptoms2/32 (6.3)
COVID-19 Severity
 Mild SARS-CoV-2 illness8/32 (25)
 Moderate SARS-CoV-2 illness4/32 (12.5)
 Severe SARS-CoV-2 illness10/32 (31.2)
 Critical SARS-CoV-2 illness/Need for admission to ICU10/32 (31.2)
Laboratory findings following development of acute pancreatitis
 Amylase levels over three times of ULN20/27 (74.1)
 Amylase levels less than three times of ULN7/27 (25.9)
 Lipase levels over three times of ULN21/22 (95.5)
 Lipase levels less than three times of ULN1/22 (0.5)
 Elevated white blood cell count12/26 (46.2)
 White blood cell count with normal limits12/26 (46.2)
 Decreased WBC count2/26 (7.6)
 Elevated levels of CRP18/20 (90)
 C-reactive protein levels within normal limits2/20 (10)
Imaging features
 Acute interstitial edematous pancreatitis21/31 (67.8)
 Necrotizing pancreatitis4/31 (12.9)
 No abnormal imaging findings3/31 (9.7)
 Abdominal CT was not performed due to pregnancy1/31 (3.2)
 Angio-abdominal CT was conducted in order to exclude ischemic changes1/31 (3.2)
 Large pancreatic pseudocyst causing a partial stomach outlet obstruction on abdominal CT1/31 (3.2)
Medical history
 Arterial hypertension11/31 (35.5)
 Diabetes mellitus6/31 (19.4)
 Obesity5/31 (16.1)
 Cholecystectomy3/31 (9.7)
 Asthma2/31 (6.5)
 Chronic kidney disease3/31 (9.7)
 Osteoporosis1/31 (3.2)
 Hypothyroidism2/31 (6.5)
 Gastroesophageal reflux1/31 (3.2)
 Hypercholesterolemia1/31 (3.2)
 Active cancer of larynx and breast1/31 (3.2)
 Thrombophilia1/31 (3.2)
 Pregnancy2/31 (6.5)
 No medical history12/31 (38.5)
Outcomes
 Recovery30/30 (100)
 Death0

Data are n (%); ULN: Upper limit of normal.

Table 5.

Data for the meta-regression meta-analysis.

#Author, YearAge/GenderSeverity of COVID-19Lipase (U/L)Amylase (U/L)
1Meyers, 2020[14]67/MSevere>3 times of UNLN/A
2Karimzadeh, 2020[15]65/FSevere>3 times of UNL<3 times of ULN
3Shinohara, 2020[16]58/MCriticalN/A>3 times of UNL
4Rabice, 2020[17]36/FSevere>3 times of UNL<3 times of ULN
5Meireles, 2020[18]36/FModerate>3 times of UNL>3 times of UNL
6Fernandes, 2020[19]36/FModerate>3 times of UNL>3 times of UNL
7Aiwaeli, 2020[20]30/MCritical>3 times of UNL<3 times of ULN
8Narang, 2020[21]20/FCritical>3 times of UNL>3 times of UNL
9Kandasamy, 2020[22]45/FSevere>3 times of UNL>3 times of UNL
10Kumaran, 2020[23]67/FSevereN/A>3 times of UNL
11Acherjya, 2020[24]57/FSevere>3 times of UNL<3 times of UNL
12Bokhari, 2020[25]32/MMild>3 times of UNL>3 times of UNL
13Mazrouei, 2020[26]24/MMild>3 times of UNL>3 times of UNL
14Patnaik, 2020[27]29/MModerate>3 times of UNL>3 times of UNL
15Schepis, 2020[28]67/FMildN/A>3 times of UNL
16Aloysius, 2020[29]36/FCritical>3 times of UNL>3 times of UNL
17Gonzalo-Voltas, 2020[30]76/FMildN/A>3 times of UNL
18Alves, 2020[31]56/FCritical>3 times of UNL>3 times of UNL
19Ghosh, 2020[32]63/MSevere<3 times of UNL<3 times of UNL
20Kataria, 2020[33]49/FCritical>3 times of UNL>3 times of UNL
21Hadi, 2020[34]47/FCriticalN/A>3 times of UNL
22Hadi, 2020[34]68/FCriticalN/A>3 times of UNL
23Brikman, 2020[35]61/MCritical>3 times of UNL<3 times of UNL
24Lakshmanan, 2020[36]68/MMild>3 times of UNL>3 times of UNL
25Miao, 2020[37]26/FMild>3 times of UNLN/A
26Pinte, 2020[38]47/MMildN/AN/A
27Anand, 2020[39]59/FMildN/AN/A
28Wifi, 2021[40]72/FSevere>3 times of UNL>3 times of UNL
29Mohammadi Arbati, 2021[41]28/MCritical>3 times of UNL>3 times of UNL
30Maalouf, 2021[42]62/MModerate>3 times of UNLN/A
31AlHarm, 2021[43]52/FSevereN/A<3 times of UNL
32Chivato Martin-Falquina, 2021[44]55/MSevereN/A>3 times of UNL

ULN: Upper limit of normal

Table 6.

Results of the regression analysis for lipase (n=24).

ParameterBeta estimatez P
ß0−.484−.780.442
ß1.7532.072.124

Severity1=−,484+753*log1(lipase)

Table 7.

Results of the regression analysis for amylase lipase (n=27).

ParameterBeta estimatez P
ß0−.484−.780.442
ß11.2231.586.042

Severity2=−,484+1,1223*log2(amylase)

  43 in total

1.  A Case of COVID-19-Induced Acute Pancreatitis.

Authors:  Matthew H Meyers; Michael J Main; Jordan K Orr; Keith L Obstein
Journal:  Pancreas       Date:  2020 Nov/Dec       Impact factor: 3.327

2.  SARS-CoV-2 and acute pancreatitis: a new etiological agent?

Authors:  Daniel Alvarenga Fernandes; Aline Satomi Yumioka; Helio Ranes de Menezes Filho
Journal:  Rev Esp Enferm Dig       Date:  2020-11       Impact factor: 2.086

3.  A basic introduction to fixed-effect and random-effects models for meta-analysis.

Authors:  Michael Borenstein; Larry V Hedges; Julian P T Higgins; Hannah R Rothstein
Journal:  Res Synth Methods       Date:  2010-11-21       Impact factor: 5.273

4.  Case Report: Novel Coronavirus-A Potential Cause of Acute Pancreatitis?

Authors:  Syed Muhammad Mashhood Ali Bokhari; Fatima Mahmood
Journal:  Am J Trop Med Hyg       Date:  2020-09       Impact factor: 2.345

5.  Emerging Phenotype of Severe Acute Respiratory Syndrome-Coronavirus 2-associated Pancreatitis.

Authors:  Peter Szatmary; Ankur Arora; Michael Godwin Thomas Raraty; Declan Francis Joseph Dunne; Ryan David Baron; Christopher Michael Halloran
Journal:  Gastroenterology       Date:  2020-06-01       Impact factor: 22.682

6.  Coronavirus disease-19 (COVID-19) associated with acute necrotising pancreatitis (ANP).

Authors:  Naren K Kumaran; Biraj K Karmakar; Ormond M Taylor
Journal:  BMJ Case Rep       Date:  2020-09-07

7.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  PLoS Med       Date:  2009-07-21       Impact factor: 11.069

8.  [Acute pancreatitis in a patient with COVID-19 infection].

Authors:  Ana Gonzalo-Voltas; Clara Uxia Fernández-Pérez-Torres; José Miguel Baena-Díez
Journal:  Med Clin (Barc)       Date:  2020-06-09       Impact factor: 1.725

9.  Coronavirus Disease-19 (COVID-19) associated with severe acute pancreatitis: Case report on three family members.

Authors:  Amer Hadi; Mikkel Werge; Klaus Tjelle Kristiansen; Ulf Gøttrup Pedersen; John Gásdal Karstensen; Srdan Novovic; Lise Lotte Gluud
Journal:  Pancreatology       Date:  2020-05-05       Impact factor: 3.977

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.